Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:BARNYSE:CRLNASDAQ:REVBNASDAQ:SKIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBARGraniteShares Gold Trust$33.11-0.5%$32.13$22.60▼$34.04$1.13B0.11977,820 shs527,219 shsCRLCharles River Laboratories International$141.34-1.3%$127.74$91.86▼$254.15$6.94B1.48990,825 shs728,930 shsREVBRevelation Biosciences$0.82-7.8%$2.69$0.77▼$60.80$786K0.19348,707 shs1.17 million shsSKINBeauty Health$1.60-4.2%$1.29$0.78▼$2.24$201.59M1.171.03 million shs599,333 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBARGraniteShares Gold Trust-0.48%+1.25%-1.93%+15.33%+42.41%CRLCharles River Laboratories International-1.38%+2.72%+22.68%-19.79%-34.60%REVBRevelation Biosciences-7.85%-7.39%-71.90%-76.65%-97.70%SKINBeauty Health-4.19%-0.62%+52.38%+23.08%-24.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBARGraniteShares Gold TrustN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.3759 of 5 stars3.12.00.04.72.62.51.9REVBRevelation Biosciences1.5274 of 5 stars0.05.00.00.03.00.01.3SKINBeauty Health0.6348 of 5 stars0.81.00.00.03.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBARGraniteShares Gold Trust 0.00N/AN/AN/ACRLCharles River Laboratories International 2.18Hold$171.8521.59% UpsideREVBRevelation Biosciences 0.00N/AN/AN/ASKINBeauty Health 1.67Reduce$1.42-11.46% DownsideCurrent Analyst Ratings BreakdownLatest BAR, SKIN, CRL, and REVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.005/5/2025SKINBeauty HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.254/10/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.004/9/2025CRLCharles River Laboratories InternationalMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.003/21/2025CRLCharles River Laboratories InternationalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$190.00 ➝ $170.003/13/2025SKINBeauty HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.75 ➝ $1.50(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBARGraniteShares Gold TrustN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.02B1.73$18.90 per share7.48$67.80 per share2.08REVBRevelation BiosciencesN/AN/AN/AN/A$402.10 per shareN/ASKINBeauty Health$322.47M0.63N/AN/A$0.48 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBARGraniteShares Gold TrustN/AN/A0.00∞N/AN/AN/AN/AN/ACRLCharles River Laboratories International$474.62M-$0.65942.2512.854.540.52%14.69%6.79%8/6/2025 (Estimated)REVBRevelation Biosciences-$120K-$102.61N/AN/AN/AN/A-193.51%-84.00%8/8/2025 (Estimated)SKINBeauty Health-$100.12M-$0.41N/AN/AN/A-8.11%-44.83%-3.54%8/14/2025 (Estimated)Latest BAR, SKIN, CRL, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025REVBRevelation Biosciences-$6.88-$2.11+$4.77-$2.11N/AN/A5/8/2025Q1 2025SKINBeauty Health-$0.13-$0.08+$0.05-$0.08$63.88 million$69.60 million5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 million3/12/2025Q4 2024SKINBeauty Health-$0.10-$0.08+$0.02-$0.08$78.02 million$83.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBARGraniteShares Gold TrustN/A0.00%N/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBARGraniteShares Gold TrustN/AN/AN/ACRLCharles River Laboratories International0.651.411.14REVBRevelation BiosciencesN/A1.641.64SKINBeauty Health9.236.565.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBARGraniteShares Gold TrustN/ACRLCharles River Laboratories International98.91%REVBRevelation Biosciences12.80%SKINBeauty Health93.26%Insider OwnershipCompanyInsider OwnershipBARGraniteShares Gold TrustN/ACRLCharles River Laboratories International1.30%REVBRevelation Biosciences0.06%SKINBeauty Health41.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBARGraniteShares Gold Trust2,02134.10 millionN/ANot OptionableCRLCharles River Laboratories International21,40049.12 million50.47 millionOptionableREVBRevelation Biosciences10964,000268,000Not OptionableSKINBeauty Health1,030125.99 million73.23 millionOptionableBAR, SKIN, CRL, and REVB HeadlinesRecent News About These CompaniesThe Winter Beauty Trends We Can’t Get Enough of for 2025June 6 at 7:13 AM | msn.comGMB dermatologist issues skin cancer warning over popular beauty trendJune 6 at 7:13 AM | mirror.co.ukBeauty expert to Queen warns over 'devastating impact' of certain skincare on younger generationJune 5 at 9:12 PM | msn.comThe AI beauty revolution is shaping the future of facesJune 5 at 9:12 PM | theaustralian.com.auSkin Experts Tele-Esthetician Program Helps You Avoid Skincare PitfallsJune 5 at 9:12 PM | usmagazine.comThere's no such thing as a safe tan: What to know about summer skin careJune 5 at 9:12 PM | msn.comWant healthy, glowing skin? Follow this 5-step skincare routineJune 5 at 9:12 PM | msn.comGlow from Head to Toe With My Beauty Editor-Approved Summer Skincare RoutineJune 5 at 2:07 AM | yahoo.comWhat Are Humectants in Hair and Skin Care Products?June 4 at 9:07 PM | msn.comThis Summer, My Beauty Editor-Approved Skincare Routine Gives Equal Love to My Body and FaceJune 4 at 4:05 PM | msn.com'I'm nearly 70 but look years younger - I won't leave the house without my go-to skin care product'June 4 at 11:05 AM | msn.comCan Cycle Syncing Your Skin Care Routine Improve Your Glow?June 4 at 11:05 AM | bustle.com5 powerful facial massage benefits transform skinJune 4 at 11:05 AM | rollingout.comBeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health TreatmentsJune 4 at 8:00 AM | globenewswire.com“Looks can kill”: Why this skin doctor says beauty is a health issueJune 3 at 1:59 PM | msn.comWhat Is a BB Cream? All About K-Beauty’s Favorite Foundation AlternativeJune 3 at 8:57 AM | vogue.comI Tried A New Injectable To Improve My Skin's Texture—And Now, My Complexion's Smoother Than EverJune 3 at 8:57 AM | msn.comKalahari melon oil: 5 benefits for healthy skinJune 3 at 3:56 AM | newsbytesapp.comRhode Skin By Hailey Bieber Review: These Beauty Essentials Have Transformed Our Beauty Team’s SkinJune 2, 2025 | msn.comThe best beauty products that A-list celebrities swear by - from moisturiser to supplementsJune 2, 2025 | rsvplive.ieMillennium Management LLC Raises Stake in The Beauty Health Company (NASDAQ:SKIN)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIs Energy Transfer Undervalued or a Value Trap?By Chris Markoch | May 8, 2025View Is Energy Transfer Undervalued or a Value Trap?TJX Stock Price Stumble Is Your Chance to Pick Up a BargainBy Thomas Hughes | May 23, 2025View TJX Stock Price Stumble Is Your Chance to Pick Up a BargainOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBy Thomas Hughes | June 3, 2025View Ollie’s Q1 Earnings: The Good, the Bad, and What’s NextBAR, SKIN, CRL, and REVB Company DescriptionsGraniteShares Gold Trust NYSEARCA:BAR$33.11 -0.16 (-0.48%) Closing price 06/5/2025 04:10 PM EasternExtended Trading$33.09 -0.02 (-0.06%) As of 07:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The GraniteShares Gold Trust (BAR) is an exchange-traded fund that is based on the LBMA Gold Price index. The fund tracks the gold spot price, less trust expenses and liabilities, using physically held gold stored and secured in vaults in London. BAR was launched on Aug 31, 2017 and is managed by GraniteShares.Charles River Laboratories International NYSE:CRL$141.34 -1.88 (-1.31%) Closing price 06/5/2025 03:59 PM EasternExtended Trading$137.28 -4.06 (-2.87%) As of 07:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Revelation Biosciences NASDAQ:REVB$0.82 -0.07 (-7.85%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$0.78 -0.03 (-3.80%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Beauty Health NASDAQ:SKIN$1.60 -0.07 (-4.19%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$1.65 +0.05 (+3.12%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
